This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
AngioDynamics (ANGO) Q2 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
AngioDynamics (ANGO) gains from core Oncology business in the fiscal second quarter, reiterates guidance.
AngioDynamics (ANGO) Beats Q2 Earnings Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 200.00% and -2.61%, respectively, for the quarter ended November 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AngioDynamics (ANGO) Q2 Earnings Expected to Decline
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is AngioDynamics (ANGO) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics Boosts VIT Product Portfolio With New Buyout
by Zacks Equity Research
AngioDynamics (ANGO) is likely to see an expansion of its already existing VIT product portfolio with the buyout of Eximo Medical.
AngioDynamics (ANGO) Q1 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
AngioDynamics (ANGO) keeps fiscal 2020 revenue guidance intact, slashes EPS view.
Luminex Gets FDA Nod for ARIES MRSA Assay, Boosts Platform
by Zacks Equity Research
Luminex (LMNX) receives FDA clearance for the ARIES MRSA assay, which is likely to provide a boost to the company's ARIES platform.
AngioDynamics (ANGO) Q1 Earnings Beat Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 100.00% and -2.32%, respectively, for the quarter ended August 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AngioDynamics (ANGO) Q1 Earnings Expected to Decline
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics (ANGO) Down 8.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates
by Zacks Equity Research
AngioDyamics (ANGO) gains from solid segmental contributions in fourth-quarter fiscal 2019.
AngioDynamics (ANGO) Lags Q4 Earnings Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -3.85% and 3.72%, respectively, for the quarter ended May 2019. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics (ANGO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics Divests NAMIC Portfolio to Medline Industries
by Zacks Equity Research
The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.
AngioDynamics IDE Application for NanoKnife Gets FDA Nod
by Zacks Equity Research
AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States.
Why Is AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics' (ANGO) Q3 Earnings & Revenues Lag Estimates
by Zacks Equity Research
Despite strength in the VIT business, AngioDynamics (ANGO) exited third-quarter fiscal 2019 on a tepid note, with both earnings and revenues missing estimates.
AngioDynamics Gets FDA Nod to Begin NanoKnife DIRECT Study
by Zacks Equity Research
AngioDynamics' (ANGO) launches AngioDIRECT.com for enrolling participants as part of the DIRECT clinical study.
AngioDynamics (ANGO) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -13.64% and -2.44%, respectively, for the quarter ended February 2019. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics' Latest FDA Approval to Boost Oncology Unit
by Zacks Equity Research
AngioDynamics' (ANGO) OARtrac is the first of its kind radiation dose monitoring platform.
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avanos (AVNS) Q4 Earnings Beat, Revenues Miss, Shares Down
by Zacks Equity Research
Avanos (AVNS) registers solid growth in the Chronic Care and Pain Management segments in Q4.
AMN Healthcare (AMN) Q4 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) Q4 results get a boost from Nurse and Allied Solutions and Other Workforce Solutions segments.
Cooper Companies' (COO) Q1 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Strong performance by Cooper Companies' (COO) CSI and CVI segments drove the top line in first-quarter fiscal 2019.
GNC Holdings' (GNC) Q4 Earnings Miss Estimates, Margins Fall
by Zacks Equity Research
GNC Holdings' (GNC) international segment registers revenue growth in the fourth quarter.